José Luis González Llerena

Mr. José Luis González Llerena

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
Luis Fernando Méndez LópezLuis Fernando Méndez López
Luis Fernando Méndez López
José Luis González LlerenaJosé Luis González Llerena
José Luis González Llerena
Jesús Alberto Vázquez-RodríguezJesús Alberto Vázquez-Rodríguez
Jesús Alberto Vázquez-Rodríguez
AGAlpha Berenice Medellín Guerrero
Alpha Berenice Medellín Guerrero
BGBlanca Edelia González-Martínez
Blanca Edelia González-Martínez
MLManuel López-Cabanillas Lomelí
Manuel López-Cabanillas Lomelí
Recent insights into the influence of nutrition on immune system components have driven the development of dietary strategies targeting the prevention and management of major metabolic-inflammatory diseases. This review summarizes the bidirectional relationship between nutrition and immunocompetence, beginning with an overview of immune system components and their functions. It examines the effects of nutritional status, dietary patterns, and food bioactives on systemic inflammation, immune cell populations, and lymphoid tissues, as well as their associations with infectious and chronic disease pathogenesis. The mechanisms by which key nutrients influence immune constituents are delineated, focusing on vitamins A, D, E, C, and B, as well as minerals including zinc, iron, and selenium. Also highlighted are the immunomodulatory effects of polyunsaturated fatty acids as well as bioactive phenolic compounds and probiotics, given their expanding relevance. Each section addresses the implications of nutritional and nutraceutical interventions involving these nutrients within the broader context of major infectious, metabolic, and inflammatory diseases. This review further underscores that, while targeted nutrient supplementation can effectively restore immune function to optimal levels, caution is necessary in certain cases, as it may increase morbidity in specific diseases. In other instances, dietary counseling should be integrated to ensure that therapeutic goals are achieved safely and effectively.

Verified
Journal Article
Open access
PDF file
José Luis González LlerenaJosé Luis González Llerena
José Luis González Llerena
BEBryan Alejandro Espinosa-Rodriguez
Bryan Alejandro Espinosa-Rodriguez
DTDaniela Treviño-Almaguer
Daniela Treviño-Almaguer
Luis Fernando Méndez LópezLuis Fernando Méndez López
Luis Fernando Méndez López
PCPilar Carranza-Rosales
Pilar Carranza-Rosales
IBIsaías Balderas-Rentería
Isaías Balderas-Rentería
Cordycepin, or 3′-deoxyadenosine, is an adenosine analog with a broad spectrum of biological activity. The key structural difference between cordycepin and adenosine lies in the absence of a hydroxyl group at the 3′ position of the ribose ring. Upon administration, cordycepin can undergo an enzymatic transformation in specific tissues, forming cordycepin triphosphate. In this study, we conducted a comprehensive analysis of the structural features of cordycepin and its derivatives, contrasting them with endogenous purine-based metabolites using chemoinformatics and bioinformatics tools in addition to molecular dynamics simulations. We tested the hypothesis that cordycepin triphosphate could bind to the active site of the adenylate cyclase enzyme. The outcomes of our molecular dynamics simulations revealed scores that are comparable to, and superior to, those of adenosine triphosphate (ATP), the endogenous ligand. This interaction could reduce the production of cyclic adenosine monophosphate (cAMP) by acting as a pseudo-ATP that lacks a hydroxyl group at the 3′ position, essential to carry out nucleotide cyclization. We discuss the implications in the context of the plasticity of cancer and other cells within the tumor microenvironment, such as cancer-associated fibroblast, endothelial, and immune cells. This interaction could awaken antitumor immunity by preventing phenotypic changes in the immune cells driven by sustained cAMP signaling. The last could be an unreported molecular mechanism that helps to explain more details about cordycepin’s mechanism of action.

24 December 2024 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
MLManuel López-Cabanillas Lomelí
Manuel López-Cabanillas Lomelí
ATAlexandra Tijerina
Alexandra Tijerina
DHDavid Gilberto Garcia Hernandez
David Gilberto Garcia Hernandez
MHMarcelo Hernández-Salazar
Marcelo Hernández-Salazar
SGSalas Rogelio García
Salas Rogelio García
MHMichel Stéphane Heya
Michel Stéphane Heya
Colon cancer (CC) is the third most frequent neoplasm, with a considerably high mortality rate. Due to the side effects of conventional forms of CC treatment (surgery, chemotherapy, and radiotherapy), several studies have focused on the use of medicinal plant derivatives to provide a green therapy for CC; although phytochemicals have shown promising results against CC, translating the results obtained in vitro and in vivo to the clinical setting remains a challenge. Indeed, like other orally applied medicines, medicinal plant derivatives have to cross different physiological barriers to reach the CC microenvironment, which considerably limits their dose-dependent therapeutic efficacy. On the other hand, phytocompounds are not free from biopharmaceutical drawbacks, so novel strategies using nanoparticles (NPs) have been proposed to overcome the physiological barriers of the body and provide controlled release of actives of interest. Accordingly, the current review provides an overview and discussion on the predisposing factors to CC and conventional treatment, the use of medicinal plants in CC treatment, and the advantages provided by NPs in the treatment of CC.

30 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
José Luis González LlerenaJosé Luis González Llerena
José Luis González Llerena
DTDaniela Treviño-Almaguer
Daniela Treviño-Almaguer
JLJesus Alejandro Leal-Mendez
Jesus Alejandro Leal-Mendez
GVGael Garcia Valdez
Gael Garcia Valdez
AGArely Guadalupe
Arely Guadalupe
BEBryan Alejandro Espinosa-Rodriguez
Bryan Alejandro Espinosa-Rodriguez
Background/Objectives: Cancer remains one of the leading causes of mortality globally, underscoring the need for novel therapeutic strategies capable of targeting multiple molecular pathways simultaneously. Natural products, particularly fungal-derived metabolites from the genus Cordyceps, represent promising candidates due to their diverse biological activities. Although previous studies have indicated the anticancer potential of Cordyceps species, systematic characterization of their molecular targets has been limited. This study aimed to comprehensively identify and evaluate Cordyceps metabolites as potential multitarget anticancer agents through a network pharmacology approach. Methods: A total of 129 metabolites previously reported in the literature from polar aqueous, alcoholic, and non-polar extracts of Cordyceps were compiled and chemically classified using ChemMine tools. Structure-based target prediction and pathway enrichment analyses were performed to investigate their potential biological targets. Predicted molecular targets were cross-referenced with differentially expressed genes in breast, colorectal, and lung cancers to identify hub proteins. Molecular docking simulations were conducted to assess binding affinities of metabolites to key oncogenic targets, and SwissADME was utilized for pharmacokinetic profiling. Results: The analysis revealed that Cordyceps metabolites targeted critical oncogenic pathways, including cell cycle regulation, DNA replication, and apoptosis. Hub proteins such as TYMS, AURKA, and CDK1 were identified as primary targets. Docking simulations highlighted metabolites such as cordycepsidone A, jiangxienone, and flazin, demonstrating binding affinities comparable or superior to clinically used inhibitors. Pharmacokinetic profiling identified several metabolites with favorable drug-like properties, supporting their potential as lead compounds. Conclusions:Cordyceps extracts contain structurally diverse metabolites capable of modulating multiple cancer-relevant molecular targets, providing a robust foundation for their development into multitarget anticancer therapies. This integrative network pharmacology approach underscores the potential of fungal metabolites in oncology drug discovery.

1 March 2023 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
IBIsaías Balderas-Rentería
Isaías Balderas-Rentería
BEBryan Alejandro Espinosa-Rodriguez
Bryan Alejandro Espinosa-Rodriguez
ANAissa Michelle Nieto-Moreno
Aissa Michelle Nieto-Moreno
José Luis González LlerenaJosé Luis González Llerena
José Luis González Llerena
TRTania Alejandra Rico-Torres
Tania Alejandra Rico-Torres
Luis Fernando Méndez LópezLuis Fernando Méndez López
Luis Fernando Méndez López
Many therapies have been developed against COVID-19 since it first appeared in December 2019. Antivirals, antimalarials, cephalosporins, colchicine, anticoagulants, and corticosteroids, among others, have been evaluated as protecting agents against antibacterial complications due to their anti-inflammatory and immunomodulatory effects against thrombosis and cell death caused by infection with SARS-CoV-2. Nevertheless, the overall balance in their application has not been found to be satisfactory. On the other hand, developing and applying several vaccines against this virus have marked an important watershed in preventive and prophylactic medicine in the new millennium. However, given the regular efficacy reported of some of them, the still scarce affordability, and the emergency of new strains for which no drug has been evaluated, the search for new pharmacological therapy alternatives still represents an essential component in the clinical management of COVID-19, and the rapid identification of drugs with potential antiviral and/or immunomodulatory properties is needed. In the present review, a potential therapeutic effect of metformin and other antidiabetic therapies for the management of COVID-19 are proposed and discussed from the viewpoint of their in vitro and in vivo immunomodulatory effects. Given that acute inflammation is an important component of COVID-19, antidiabetic therapies could be promising alternatives in its management and reducing the disease's severity. In order to understand how metformin and other antidiabetic therapies could work in the context of COVID-19, here we review the possible mechanisms of action through a detailed description of cellular and molecular events.

1 November 2025
Verified
Book Chapter
Closed access
PDF file
DTDaniela Treviño-Almaguer
Daniela Treviño-Almaguer
BEBryan Alejandro Espinosa-Rodríguez
Bryan Alejandro Espinosa-Rodríguez
IBIsaías Balderas-Rentería
Isaías Balderas-Rentería
José Luis González LlerenaJosé Luis González Llerena
José Luis González Llerena